STOCKHOLM, Feb. 6, 2024 /PRNewswire/ — BioArctic AB’s (publ) (STO: BIOA-B) partner Eisai today issued their quarterly report containing Leqembi sales for the fourth quarter 2023 (third quarter of Eisai’s fiscal year, ending March 2024). In total, sales of JPY 1.1 billion were recorded in…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.